Global Bispecific T Cell Engager Therapeutics Market Research Report 2023

Bispecific T Cell Engager Therapeutics Market

Bispecific T cell-engagers (BiTEs) are small antibody-based molecules composed of two antigen-binding single-chain variable fragments (scFvs) genetically fused by a flexible peptide linker and capable of redirecting T cells against tumour-associated antigen (TAA)-bearing cancer cells.By binding T cells and tumor cells through the specific structure, bispecific T cell engagers enhance tumor lysis effectually and provide relapse/refractory patients with feasible options regardless of mutations or T cell dysfunction.

The global Bispecific T Cell Engager Therapeutics market was valued at US$ million in 2022 and is anticipated to reach US$ million by 2029, witnessing a CAGR of % during the forecast period 2023-2029. The influence of COVID-19 and the Russia-Ukraine War were considered while estimating market sizes.

North American market for Bispecific T Cell Engager Therapeutics is estimated to increase from $ million in 2023 to reach $ million by 2029, at a CAGR of % during the forecast period of 2023 through 2029.

Asia-Pacific market for Bispecific T Cell Engager Therapeutics is estimated to increase from $ million in 2023 to reach $ million by 2029, at a CAGR of % during the forecast period of 2023 through 2029.

The global market for Bispecific T Cell Engager Therapeutics in Hospital is estimated to increase from $ million in 2023 to $ million by 2029, at a CAGR of % during the forecast period of 2023 through 2029.

The key global companies of Bispecific T Cell Engager Therapeutics include LAVA, Amgen, Takeda, Merck, Nk pharma, Seagen Inc. and BPS Bioscience, etc. In 2022, the world's top three vendors accounted for approximately % of the revenue.

Report Scope

This report aims to provide a comprehensive presentation of the global market for Bispecific T Cell Engager Therapeutics, with both quantitative and qualitative analysis, to help readers develop business/growth strategies, assess the market competitive situation, analyze their position in the current marketplace, and make informed business decisions regarding Bispecific T Cell Engager Therapeutics.

The Bispecific T Cell Engager Therapeutics market size, estimations, and forecasts are provided in terms of and revenue ($ millions), considering 2022 as the base year, with history and forecast data for the period from 2018 to 2029. This report segments the global Bispecific T Cell Engager Therapeutics market comprehensively. Regional market sizes, concerning products by type, by application, and by players, are also provided.

For a more in-depth understanding of the market, the report provides profiles of the competitive landscape, key competitors, and their respective market ranks. The report also discusses technological trends and new product developments.

The report will help the Bispecific T Cell Engager Therapeutics companies, new entrants, and industry chain related companies in this market with information on the revenues for the overall market and the sub-segments across the different segments, by company, by type, by application, and by regions.

Scope of Bispecific T Cell Engager Therapeutics Market Report

Core Chapters

1.1 Study Scope

1.2 Market Analysis by Type

1.2.1 Global Bispecific T Cell Engager Therapeutics Market Size Growth Rate by Type: 2018 VS 2022 VS 2029

1.2.2 Heavy Chains

1.2.3 Light Chains

1.3 Market by Application

1.3.1 Global Bispecific T Cell Engager Therapeutics Market Growth by Application: 2018 VS 2022 VS 2029

1.3.2 Hospital

1.3.3 Laboratorios

1.3.4 Others

1.4 Study Objectives

1.5 Years Considered

1.6 Years Considered

2.1 Global Bispecific T Cell Engager Therapeutics Market Perspective (2018-2029)

2.2 Bispecific T Cell Engager Therapeutics Growth Trends by Region

2.2.1 Global Bispecific T Cell Engager Therapeutics Market Size by Region: 2018 VS 2022 VS 2029

2.2.2 Bispecific T Cell Engager Therapeutics Historic Market Size by Region (2018-2023)

2.2.3 Bispecific T Cell Engager Therapeutics Forecasted Market Size by Region (2024-2029)

2.3 Bispecific T Cell Engager Therapeutics Market Dynamics

2.3.1 Bispecific T Cell Engager Therapeutics Industry Trends

2.3.2 Bispecific T Cell Engager Therapeutics Market Drivers

2.3.3 Bispecific T Cell Engager Therapeutics Market Challenges

2.3.4 Bispecific T Cell Engager Therapeutics Market Restraints

3.1 Global Top Bispecific T Cell Engager Therapeutics Players by Revenue

3.1.1 Global Top Bispecific T Cell Engager Therapeutics Players by Revenue (2018-2023)

3.1.2 Global Bispecific T Cell Engager Therapeutics Revenue Market Share by Players (2018-2023)

3.2 Global Bispecific T Cell Engager Therapeutics Market Share by Company Type (Tier 1, Tier 2, and Tier 3)

3.3 Players Covered: Ranking by Bispecific T Cell Engager Therapeutics Revenue

3.4 Global Bispecific T Cell Engager Therapeutics Market Concentration Ratio

3.4.1 Global Bispecific T Cell Engager Therapeutics Market Concentration Ratio (CR5 and HHI)

3.4.2 Global Top 10 and Top 5 Companies by Bispecific T Cell Engager Therapeutics Revenue in 2022

3.5 Bispecific T Cell Engager Therapeutics Key Players Head office and Area Served

3.6 Key Players Bispecific T Cell Engager Therapeutics Product Solution and Service

3.7 Date of Enter into Bispecific T Cell Engager Therapeutics Market

3.8 Mergers & Acquisitions, Expansion Plans

4.1 Global Bispecific T Cell Engager Therapeutics Historic Market Size by Type (2018-2023)

4.2 Global Bispecific T Cell Engager Therapeutics Forecasted Market Size by Type (2024-2029)

5.1 Global Bispecific T Cell Engager Therapeutics Historic Market Size by Application (2018-2023)

5.2 Global Bispecific T Cell Engager Therapeutics Forecasted Market Size by Application (2024-2029)

6.1 North America Bispecific T Cell Engager Therapeutics Market Size (2018-2029)

6.2 North America Bispecific T Cell Engager Therapeutics Market Growth Rate by Country: 2018 VS 2022 VS 2029

6.3 North America Bispecific T Cell Engager Therapeutics Market Size by Country (2018-2023)

6.4 North America Bispecific T Cell Engager Therapeutics Market Size by Country (2024-2029)

6.5 United States

6.6 Canada

7.1 Europe Bispecific T Cell Engager Therapeutics Market Size (2018-2029)

7.2 Europe Bispecific T Cell Engager Therapeutics Market Growth Rate by Country: 2018 VS 2022 VS 2029

7.3 Europe Bispecific T Cell Engager Therapeutics Market Size by Country (2018-2023)

7.4 Europe Bispecific T Cell Engager Therapeutics Market Size by Country (2024-2029)

7.5 Germany

7.6 France

7.7 U.K.

7.8 Italy

7.9 Russia

7.10 Nordic Countries

8.1 Asia-Pacific Bispecific T Cell Engager Therapeutics Market Size (2018-2029)

8.2 Asia-Pacific Bispecific T Cell Engager Therapeutics Market Growth Rate by Region: 2018 VS 2022 VS 2029

8.3 Asia-Pacific Bispecific T Cell Engager Therapeutics Market Size by Region (2018-2023)

8.4 Asia-Pacific Bispecific T Cell Engager Therapeutics Market Size by Region (2024-2029)

8.5 China

8.6 Japan

8.7 South Korea

8.8 Southeast Asia

8.9 India

8.10 Australia

9.1 Latin America Bispecific T Cell Engager Therapeutics Market Size (2018-2029)

9.2 Latin America Bispecific T Cell Engager Therapeutics Market Growth Rate by Country: 2018 VS 2022 VS 2029

9.3 Latin America Bispecific T Cell Engager Therapeutics Market Size by Country (2018-2023)

9.4 Latin America Bispecific T Cell Engager Therapeutics Market Size by Country (2024-2029)

9.5 Mexico

9.6 Brazil

10.1 Middle East & Africa Bispecific T Cell Engager Therapeutics Market Size (2018-2029)

10.2 Middle East & Africa Bispecific T Cell Engager Therapeutics Market Growth Rate by Country: 2018 VS 2022 VS 2029

10.3 Middle East & Africa Bispecific T Cell Engager Therapeutics Market Size by Country (2018-2023)

10.4 Middle East & Africa Bispecific T Cell Engager Therapeutics Market Size by Country (2024-2029)

10.5 Turkey

10.6 Saudi Arabia

10.7 UAE

11.1 LAVA

11.1.1 LAVA Company Detail

11.1.2 LAVA Business Overview

11.1.3 LAVA Bispecific T Cell Engager Therapeutics Introduction

11.1.4 LAVA Revenue in Bispecific T Cell Engager Therapeutics Business (2018-2023)

11.1.5 LAVA Recent Development

11.2 Amgen

11.2.1 Amgen Company Detail

11.2.2 Amgen Business Overview

11.2.3 Amgen Bispecific T Cell Engager Therapeutics Introduction

11.2.4 Amgen Revenue in Bispecific T Cell Engager Therapeutics Business (2018-2023)

11.2.5 Amgen Recent Development

11.3 Takeda

11.3.1 Takeda Company Detail

11.3.2 Takeda Business Overview

11.3.3 Takeda Bispecific T Cell Engager Therapeutics Introduction

11.3.4 Takeda Revenue in Bispecific T Cell Engager Therapeutics Business (2018-2023)

11.3.5 Takeda Recent Development

11.4 Merck

11.4.1 Merck Company Detail

11.4.2 Merck Business Overview

11.4.3 Merck Bispecific T Cell Engager Therapeutics Introduction

11.4.4 Merck Revenue in Bispecific T Cell Engager Therapeutics Business (2018-2023)

11.4.5 Merck Recent Development

11.5 Nk pharma

11.5.1 Nk pharma Company Detail

11.5.2 Nk pharma Business Overview

11.5.3 Nk pharma Bispecific T Cell Engager Therapeutics Introduction

11.5.4 Nk pharma Revenue in Bispecific T Cell Engager Therapeutics Business (2018-2023)

11.5.5 Nk pharma Recent Development

11.6 Seagen Inc.

11.6.1 Seagen Inc. Company Detail

11.6.2 Seagen Inc. Business Overview

11.6.3 Seagen Inc. Bispecific T Cell Engager Therapeutics Introduction

11.6.4 Seagen Inc. Revenue in Bispecific T Cell Engager Therapeutics Business (2018-2023)

11.6.5 Seagen Inc. Recent Development

11.7 BPS Bioscience

11.7.1 BPS Bioscience Company Detail

11.7.2 BPS Bioscience Business Overview

11.7.3 BPS Bioscience Bispecific T Cell Engager Therapeutics Introduction

11.7.4 BPS Bioscience Revenue in Bispecific T Cell Engager Therapeutics Business (2018-2023)

11.7.5 BPS Bioscience Recent Development

13.1 Research Methodology

13.1.1 Methodology/Research Approach

13.1.2 Data Source

13.2 Disclaimer

13.3 Author Details

List of Tables

    Table 1. Global Bispecific T Cell Engager Therapeutics Market Size Growth Rate by Type (US$ Million): 2018 VS 2022 VS 2029

    Table 2. Key Players of Heavy Chains

    Table 3. Key Players of Light Chains

    Table 4. Global Bispecific T Cell Engager Therapeutics Market Size Growth by Application (US$ Million): 2018 VS 2022 VS 2029

    Table 5. Global Bispecific T Cell Engager Therapeutics Market Size by Region (US$ Million): 2018 VS 2022 VS 2029

    Table 6. Global Bispecific T Cell Engager Therapeutics Market Size by Region (2018-2023) & (US$ Million)

    Table 7. Global Bispecific T Cell Engager Therapeutics Market Share by Region (2018-2023)

    Table 8. Global Bispecific T Cell Engager Therapeutics Forecasted Market Size by Region (2024-2029) & (US$ Million)

    Table 9. Global Bispecific T Cell Engager Therapeutics Market Share by Region (2024-2029)

    Table 10. Bispecific T Cell Engager Therapeutics Market Trends

    Table 11. Bispecific T Cell Engager Therapeutics Market Drivers

    Table 12. Bispecific T Cell Engager Therapeutics Market Challenges

    Table 13. Bispecific T Cell Engager Therapeutics Market Restraints

    Table 14. Global Bispecific T Cell Engager Therapeutics Revenue by Players (2018-2023) & (US$ Million)

    Table 15. Global Bispecific T Cell Engager Therapeutics Market Share by Players (2018-2023)

    Table 16. Global Top Bispecific T Cell Engager Therapeutics Players by Company Type (Tier 1, Tier 2, and Tier 3) & (based on the Revenue in Bispecific T Cell Engager Therapeutics as of 2022)

    Table 17. Ranking of Global Top Bispecific T Cell Engager Therapeutics Companies by Revenue (US$ Million) in 2022

    Table 18. Global 5 Largest Players Market Share by Bispecific T Cell Engager Therapeutics Revenue (CR5 and HHI) & (2018-2023)

    Table 19. Key Players Headquarters and Area Served

    Table 20. Key Players Bispecific T Cell Engager Therapeutics Product Solution and Service

    Table 21. Date of Enter into Bispecific T Cell Engager Therapeutics Market

    Table 22. Mergers & Acquisitions, Expansion Plans

    Table 23. Global Bispecific T Cell Engager Therapeutics Market Size by Type (2018-2023) & (US$ Million)

    Table 24. Global Bispecific T Cell Engager Therapeutics Revenue Market Share by Type (2018-2023)

    Table 25. Global Bispecific T Cell Engager Therapeutics Forecasted Market Size by Type (2024-2029) & (US$ Million)

    Table 26. Global Bispecific T Cell Engager Therapeutics Revenue Market Share by Type (2024-2029)

    Table 27. Global Bispecific T Cell Engager Therapeutics Market Size by Application (2018-2023) & (US$ Million)

    Table 28. Global Bispecific T Cell Engager Therapeutics Revenue Market Share by Application (2018-2023)

    Table 29. Global Bispecific T Cell Engager Therapeutics Forecasted Market Size by Application (2024-2029) & (US$ Million)

    Table 30. Global Bispecific T Cell Engager Therapeutics Revenue Market Share by Application (2024-2029)

    Table 31. North America Bispecific T Cell Engager Therapeutics Market Size Growth Rate by Country (US$ Million): 2018 VS 2022 VS 2029

    Table 32. North America Bispecific T Cell Engager Therapeutics Market Size by Country (2018-2023) & (US$ Million)

    Table 33. North America Bispecific T Cell Engager Therapeutics Market Size by Country (2024-2029) & (US$ Million)

    Table 34. Europe Bispecific T Cell Engager Therapeutics Market Size Growth Rate by Country (US$ Million): 2018 VS 2022 VS 2029

    Table 35. Europe Bispecific T Cell Engager Therapeutics Market Size by Country (2018-2023) & (US$ Million)

    Table 36. Europe Bispecific T Cell Engager Therapeutics Market Size by Country (2024-2029) & (US$ Million)

    Table 37. Asia-Pacific Bispecific T Cell Engager Therapeutics Market Size Growth Rate by Region (US$ Million): 2018 VS 2022 VS 2029

    Table 38. Asia-Pacific Bispecific T Cell Engager Therapeutics Market Size by Region (2018-2023) & (US$ Million)

    Table 39. Asia-Pacific Bispecific T Cell Engager Therapeutics Market Size by Region (2024-2029) & (US$ Million)

    Table 40. Latin America Bispecific T Cell Engager Therapeutics Market Size Growth Rate by Country (US$ Million): 2018 VS 2022 VS 2029

    Table 41. Latin America Bispecific T Cell Engager Therapeutics Market Size by Country (2018-2023) & (US$ Million)

    Table 42. Latin America Bispecific T Cell Engager Therapeutics Market Size by Country (2024-2029) & (US$ Million)

    Table 43. Middle East & Africa Bispecific T Cell Engager Therapeutics Market Size Growth Rate by Country (US$ Million): 2018 VS 2022 VS 2029

    Table 44. Middle East & Africa Bispecific T Cell Engager Therapeutics Market Size by Country (2018-2023) & (US$ Million)

    Table 45. Middle East & Africa Bispecific T Cell Engager Therapeutics Market Size by Country (2024-2029) & (US$ Million)

    Table 46. LAVA Company Detail

    Table 47. LAVA Business Overview

    Table 48. LAVA Bispecific T Cell Engager Therapeutics Product

    Table 49. LAVA Revenue in Bispecific T Cell Engager Therapeutics Business (2018-2023) & (US$ Million)

    Table 50. LAVA Recent Development

    Table 51. Amgen Company Detail

    Table 52. Amgen Business Overview

    Table 53. Amgen Bispecific T Cell Engager Therapeutics Product

    Table 54. Amgen Revenue in Bispecific T Cell Engager Therapeutics Business (2018-2023) & (US$ Million)

    Table 55. Amgen Recent Development

    Table 56. Takeda Company Detail

    Table 57. Takeda Business Overview

    Table 58. Takeda Bispecific T Cell Engager Therapeutics Product

    Table 59. Takeda Revenue in Bispecific T Cell Engager Therapeutics Business (2018-2023) & (US$ Million)

    Table 60. Takeda Recent Development

    Table 61. Merck Company Detail

    Table 62. Merck Business Overview

    Table 63. Merck Bispecific T Cell Engager Therapeutics Product

    Table 64. Merck Revenue in Bispecific T Cell Engager Therapeutics Business (2018-2023) & (US$ Million)

    Table 65. Merck Recent Development

    Table 66. Nk pharma Company Detail

    Table 67. Nk pharma Business Overview

    Table 68. Nk pharma Bispecific T Cell Engager Therapeutics Product

    Table 69. Nk pharma Revenue in Bispecific T Cell Engager Therapeutics Business (2018-2023) & (US$ Million)

    Table 70. Nk pharma Recent Development

    Table 71. Seagen Inc. Company Detail

    Table 72. Seagen Inc. Business Overview

    Table 73. Seagen Inc. Bispecific T Cell Engager Therapeutics Product

    Table 74. Seagen Inc. Revenue in Bispecific T Cell Engager Therapeutics Business (2018-2023) & (US$ Million)

    Table 75. Seagen Inc. Recent Development

    Table 76. BPS Bioscience Company Detail

    Table 77. BPS Bioscience Business Overview

    Table 78. BPS Bioscience Bispecific T Cell Engager Therapeutics Product

    Table 79. BPS Bioscience Revenue in Bispecific T Cell Engager Therapeutics Business (2018-2023) & (US$ Million)

    Table 80. BPS Bioscience Recent Development

    Table 81. Research Programs/Design for This Report

    Table 82. Key Data Information from Secondary Sources

    Table 83. Key Data Information from Primary Sources

List of Figures

    Figure 1. Global Bispecific T Cell Engager Therapeutics Market Size Comparison by Type (2023-2029) & (US$ Million)

    Figure 2. Global Bispecific T Cell Engager Therapeutics Market Share by Type: 2022 VS 2029

    Figure 3. Heavy Chains Features

    Figure 4. Light Chains Features

    Figure 5. Global Bispecific T Cell Engager Therapeutics Market Size Comparison by Application (2023-2029) & (US$ Million)

    Figure 6. Global Bispecific T Cell Engager Therapeutics Market Share by Application: 2022 VS 2029

    Figure 7. Hospital Case Studies

    Figure 8. Laboratorios Case Studies

    Figure 9. Others Case Studies

    Figure 10. Bispecific T Cell Engager Therapeutics Report Years Considered

    Figure 11. Global Bispecific T Cell Engager Therapeutics Market Size (US$ Million), Year-over-Year: 2018-2029

    Figure 12. Global Bispecific T Cell Engager Therapeutics Market Size, (US$ Million), 2018 VS 2022 VS 2029

    Figure 13. Global Bispecific T Cell Engager Therapeutics Market Share by Region: 2022 VS 2029

    Figure 14. Global Bispecific T Cell Engager Therapeutics Market Share by Players in 2022

    Figure 15. Global Top Bispecific T Cell Engager Therapeutics Players by Company Type (Tier 1, Tier 2, and Tier 3) & (based on the Revenue in Bispecific T Cell Engager Therapeutics as of 2022)

    Figure 16. The Top 10 and 5 Players Market Share by Bispecific T Cell Engager Therapeutics Revenue in 2022

    Figure 17. North America Bispecific T Cell Engager Therapeutics Market Size YoY Growth (2018-2029) & (US$ Million)

    Figure 18. North America Bispecific T Cell Engager Therapeutics Market Share by Country (2018-2029)

    Figure 19. United States Bispecific T Cell Engager Therapeutics Market Size YoY Growth (2018-2029) & (US$ Million)

    Figure 20. Canada Bispecific T Cell Engager Therapeutics Market Size YoY Growth (2018-2029) & (US$ Million)

    Figure 21. Europe Bispecific T Cell Engager Therapeutics Market Size YoY Growth (2018-2029) & (US$ Million)

    Figure 22. Europe Bispecific T Cell Engager Therapeutics Market Share by Country (2018-2029)

    Figure 23. Germany Bispecific T Cell Engager Therapeutics Market Size YoY Growth (2018-2029) & (US$ Million)

    Figure 24. France Bispecific T Cell Engager Therapeutics Market Size YoY Growth (2018-2029) & (US$ Million)

    Figure 25. U.K. Bispecific T Cell Engager Therapeutics Market Size YoY Growth (2018-2029) & (US$ Million)

    Figure 26. Italy Bispecific T Cell Engager Therapeutics Market Size YoY Growth (2018-2029) & (US$ Million)

    Figure 27. Russia Bispecific T Cell Engager Therapeutics Market Size YoY Growth (2018-2029) & (US$ Million)

    Figure 28. Nordic Countries Bispecific T Cell Engager Therapeutics Market Size YoY Growth (2018-2029) & (US$ Million)

    Figure 29. Asia-Pacific Bispecific T Cell Engager Therapeutics Market Size YoY Growth (2018-2029) & (US$ Million)

    Figure 30. Asia-Pacific Bispecific T Cell Engager Therapeutics Market Share by Region (2018-2029)

    Figure 31. China Bispecific T Cell Engager Therapeutics Market Size YoY Growth (2018-2029) & (US$ Million)

    Figure 32. Japan Bispecific T Cell Engager Therapeutics Market Size YoY Growth (2018-2029) & (US$ Million)

    Figure 33. South Korea Bispecific T Cell Engager Therapeutics Market Size YoY Growth (2018-2029) & (US$ Million)

    Figure 34. Southeast Asia Bispecific T Cell Engager Therapeutics Market Size YoY Growth (2018-2029) & (US$ Million)

    Figure 35. India Bispecific T Cell Engager Therapeutics Market Size YoY Growth (2018-2029) & (US$ Million)

    Figure 36. Australia Bispecific T Cell Engager Therapeutics Market Size YoY Growth (2018-2029) & (US$ Million)

    Figure 37. Latin America Bispecific T Cell Engager Therapeutics Market Size YoY Growth (2018-2029) & (US$ Million)

    Figure 38. Latin America Bispecific T Cell Engager Therapeutics Market Share by Country (2018-2029)

    Figure 39. Mexico Bispecific T Cell Engager Therapeutics Market Size YoY Growth (2018-2029) & (US$ Million)

    Figure 40. Brazil Bispecific T Cell Engager Therapeutics Market Size YoY Growth (2018-2029) & (US$ Million)

    Figure 41. Middle East & Africa Bispecific T Cell Engager Therapeutics Market Size YoY Growth (2018-2029) & (US$ Million)

    Figure 42. Middle East & Africa Bispecific T Cell Engager Therapeutics Market Share by Country (2018-2029)

    Figure 43. Turkey Bispecific T Cell Engager Therapeutics Market Size YoY Growth (2018-2029) & (US$ Million)

    Figure 44. Saudi Arabia Bispecific T Cell Engager Therapeutics Market Size YoY Growth (2018-2029) & (US$ Million)

    Figure 45. LAVA Revenue Growth Rate in Bispecific T Cell Engager Therapeutics Business (2018-2023)

    Figure 46. Amgen Revenue Growth Rate in Bispecific T Cell Engager Therapeutics Business (2018-2023)

    Figure 47. Takeda Revenue Growth Rate in Bispecific T Cell Engager Therapeutics Business (2018-2023)

    Figure 48. Merck Revenue Growth Rate in Bispecific T Cell Engager Therapeutics Business (2018-2023)

    Figure 49. Nk pharma Revenue Growth Rate in Bispecific T Cell Engager Therapeutics Business (2018-2023)

    Figure 50. Seagen Inc. Revenue Growth Rate in Bispecific T Cell Engager Therapeutics Business (2018-2023)

    Figure 51. BPS Bioscience Revenue Growth Rate in Bispecific T Cell Engager Therapeutics Business (2018-2023)

    Figure 52. Bottom-up and Top-down Approaches for This Report

    Figure 53. Data Triangulation

    Figure 54. Key Executives Interviewed